Incidence, risk factors of injection site reactions with degarelix investigated
the ONA take:
In a recent study, investigators sought to determine the incidence of injection site reactions (ISRs) after administration of degarelix as well as identify the risk factors for ISRs.
The study involved 50 men receiving subcutaneous therapy for the first time. The men received 240 mg degarelix, administered as two 3-mL subcutaneous injections.
Mean age of patients was 75.6 years, and mean prostate-specific antigen (PSA) level just before degarelix administration was 198.4 ng/mL.
Thirty-three patients received hormonal therapy with degarelix for the first time; 11 patients were receiving an oral steroid (six for prostate cancer, one for hematologic disease, and four for allergic conditions).
Injection site reactions were observed in 25 patients, all categorized as grade 1 or 2. Two patients discontinued digarelix due to ISR. Study findings showed incidence of ISRs in patients receiving subcutaneous therapy for the first time was 64%; incidence of ISRs in patients also receiving an oral steroid was 18%.
The investigators recommend patient education include information on the possibility of ISR due to degarelix prior to administration, especially patients who are not receiving steroids and those who have no experience with subcutaneous injections.
Investigators sought to determine the incidence of injection site reactions after administration of degarelix.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Vitamin D3 Supplementation Has No Impact on Breast Density Percentage, Breast Cancer Risk
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
- Oropharyngeal Mucositis Pain Effectively Relieved With Indomethacin Oral Spray
- Opioids Overprescribed in Patients Undergoing Surgery
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|